PR86172

HYDERABAD, India and TORONTO, Oct. 21, 2020 /PRNewswire=KYODO JBN/ --

     Excelra (https://www.excelra.com/ ), a leading global Data & Analytics

organization, today announced that it has licensed its Global Online Structure

Activity Relationship Database (GOSTAR) to Cyclica Inc., a leading

biotechnology company whose AI-augmented integrated platform enables

multi-objective, polypharmacology-informed design of drug molecules.

    GOSTAR (https://www.excelra.com/discovery/#gostar ) is the largest online

structure activity relationship database comprising of over 5.5 million small

molecules and their associated chemical, biological and pharmacological

properties. The database is manually curated by our scientific team who excerpt

and enrich datasets from functional assays, in vitro and in vivo studies. A variety

of small molecule activities encompassing SAR, physicochemical, metabolic,

ADME and toxicological profiles are captured and structured into a relational

database. GOSTAR ultimately equips researchers with insights to generate novel

ideas in drug design in the early as well as optimization stages of drug discovery.

   Dr. Raveendra Dayam, Director, Chemistry Services, Excelra said: "GOSTAR

provides access to more than 28 million experimentally determined quantitative

interactions between small molecules and the vast druggable target space.

Insights derived from these interactions complement Cyclica's polypharmacology

approach in novel compound drug discovery. GOSTAR is a rich qualitative and

quantitative dataset that is applied by many AI/ML companies and we are excited

that the data will support Cyclica with its predictive analytics."

    The breadth of data provided by GOSTAR will broaden the domain of

applicability of Cyclica's models, as Dr. Stephen MacKinnon, VP of R&D at

Cyclica indicates: "The collaboration with GOSTAR strengthens Cyclica's

training data for our platform models by allowing Cyclica to annotate our

proteome screening data, thus enhancing our predicted interaction capabilities.

This will have a direct impact on the development of more precise and

efficacious medicines for patients in need."

    About Cyclica

    Cyclica is the first company to approach polypharmacology with a

structure-based, AI-augmented in silico discovery platform, centered on 'Ligand

Design' and 'Ligand Express'. Powered by MatchMaker(TM), a proprietary deep

learning proteome screening technology, and POEM(TM), an innovative supervised

learning technology for predicting molecular properties. To know more, visit  

www.cyclicarx.com 

    About Excelra:

    Excelra's data and analytics solutions empower innovation in life sciences

from molecule to market. The Excelra Edge comes from a seamless amalgamation of

proprietary data assets, domain expertise and data science to accelerate drug

discovery and development. To know more, visit www.excelra.com

    Media Contact:

    Dorothy Paul – Director Marketing

    Email:  dorothy.paul@excelra.com

    Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg 

    Source: Excelra Knowledge Solutions Pvt Ltd